Banyu Pharmaceutical Co. Ltd

Taiho Pharmaceutical Company Limited

Msd K.k.

Yoshikazu Iwasawa

Sachie Arai

Kumiko Kawakami

Tetsuya Aoyama

Yoshiaki Monden

Toshihiko Satoh

Masahiro Hayashi

Yasufumi Nagata

Takashi Nomoto

Jun Shibata

Morihiro Mitsuya

Katsumasa Nonoshita

Yoshiaki Iida

Toshio Kamei

Mitsuru Ohkubo

Yoshimi Tsuchiya

Hiroshi Kawamoto

Nobuhiko Kawanishi

Takeshi Sagara

Takashi Mita

Masato Nanri

Tetsuya Kato

Shinichi Aoki

Fukumitsu Sakakibara

Satoshi Ozaki

Mikako Kawamura

Takashi Hashihayata

Yumiko Sakuma

Hitoshi Masaki

Tadashi Shimamura

Fuyuki Yamamoto

Osamu Okamoto

Hiroshi Hirai

Akira Naya

Satoshi Sunami

Hideki Kurihara

Tetsuya Sugimoto

Hisashi Ohta

Masaya Hashimoto

Kenji Ohwaki

Yoshiyuki Sato

Masaaki Hosoi

Yoshio Sawasaki

Kensuke Kobayashi

Atsushi Satoh

Hideya Komatani

Kyoko Hayashi

Kaori Kamijo

Satoru Itoh

Toshihiko Saeki

Kouta Masutani

Hiromi Hattori

Akiko Shimizu

Hiroki Sakoh

Masahiro Horie

Hiroshi Takezawa

Mari Yonemoto

Kenji Tanaka

Yufu Owada

Yoshiki Ito

Kaori Hirano

Izumi Yamamoto

An acetic acid ester compound represented by the following formula (I) or a salt thereof, wherein R represents optionally substituted deuterated lower alkyl, is disclosed.

Acetic acid ester compound or salt thereof

The present invention relates to a compound of formula I:  

Aminopyridine derivatives having aurora A selective inhibitory action

The present invention relates to a compound represented by Formula [I] or a pharmaceutically acceptable salt or ester thereof: wherein:

Substituted imidazole derivative

The present invention relates to a compound represented by Formula [I]: wherein

Selective inhibitors against Cdk4 and Cdk6 having aminothiazole skeleton

The invention provides the compounds represented by the formula (I) 

N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives

This invention relates to the compounds represented by a general formula [I]:[in which Aand Arepresent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C-Caliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

Benzimidazole derivatives

The present invention relates to a compound represented by Formula &lsqb;I&rsqb;

2-oxoimidazole derivatives

Chemokine receptor antagonists

Medicinal composition

Substituted amide derivatives

The present invention relates to a compound of the formula (I): ##STR1## wherein Ar.sup.1, Ar.sup.2, Ar.sup.3 and Ar.sup.4 represent an aryl group or a heteroaromatic ring group; A represents a hydrocarbon group which may be substituted; X and Y represent an oxygen atom, a sulfur atom, a carbonyl group or a group of the formula --CHR.sup.a -- (wherein R.sup.a is a hydrogen atom or a lower alkyl group) or --NR.sup.b -- (wherein R.sup.b is a hydrogen atom or a lower alkyl group), or X and Y together represent a vinylene group or an ethynylene group; R.sup.1, R.sup.2, R.sup.3, R.sup.8 and R.sup.9 represent a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a lower alkoxy group; R.sup.4 and R.sup.5 represent a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkyl group, a lower hydroxyalkyl group, a lower fluoroalkyl group or a lower alkoxy group; R.sup.6 is a lower alkyl group; and R.sup.7 is a hydrogen atom or a lower alkyl group, provided that when one of X and Y is an oxygen atom, a sulfur atom or a group of the formula --NR.sup.b --, the other is a carbonyl group or a group of the formula --CHR.sup.a --, its pharmaceutically acceptable salt or ester, and an antitumor agent containing it as an active ingredient.

N,N-disubstituted amic acid derivatives

Cyclic amic acid derivatives

The present invention relates to a compound of the formula (I): ##STR1## wherein Ar.sup.1, Ar.sup.2, Ar.sup.3 and Ar.sup.4 represent an aryl group or a heteroaromatic ring group; A represents a hydrocarbon group which may be substituted; X and Y represent an oxygen atom, a sulfur atom, a carbonyl group or a group of the formula --CHR.sup.a -- (wherein R.sup.a is a hydrogen atom or a lower alkyl group) or --NR.sup.b -- (wherein R.sup.b is a hydrogen atom or a lower alkyl group), or X and Y together represent a vinylene group or an ethynylene group; R.sup.1, R.sup.2, R.sup.3, R.sup.8 and R.sup.9 represent a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a lower alkoxy group; R.sup.4 and R.sup.5 represent a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxyl group, a lower alkoxycarbonyl group, a carbamoyl group, a lower alkylcarbamoyl group, a lower alkyl group, a lower hydroxyalkyl group, a lower fluoroalkyl group or a lower alkoxy group, R.sup.6 is a lower alkyl group, and R.sup.7 is a hydrogen atom or a lower alkyl group, provided that when one of X and Y is an oxygen atom, a sulfur atom or a group of the formula --NR.sup.b --, the other is a carbonyl group or a group of the formula --CHR.sup.a --, its pharmaceutically acceptable salt or ester, and an antitumor agent containing it as an active ingredient.

Growing community of inventors

Tsukuba, Japan

Yoshikazu Iwasawa